NCI Seeks Toxicity Studies of Five Natural Substances

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 1
Volume 9
Issue 1

 RESEARCH TRIANGLE PARK, NC—The National Toxicology Program is considering an NCI request that it do toxicity studies of four herbal products and a substance found in vegetables: aloe vera, used in cosmetics and as a dietary supplement; ginseng, promoted to increase vigor; kava kava, sold as a mood elevator; milk thistle, believed by some to prevent cancer and protect the liver; and indole-3-carbinol, which occurs in cruciferous

 RESEARCH TRIANGLE PARK, NC—The National Toxicology Program is considering an NCI request that it do toxicity studies of four herbal products and a substance found in vegetables: aloe vera, used in cosmetics and as a dietary supplement; ginseng, promoted to increase vigor; kava kava, sold as a mood elevator; milk thistle, believed by some to prevent cancer and protect the liver; and indole-3-carbinol, which occurs in cruciferous vegetables, and, according to some evidence, may reduce cancer risk.

Articles in this issue
New Strategies for Treating Ovarian Cancer
Researchers See More Effective Lung Cancer Screening, Therapy
Goserelin Reduces Breast Ca Recurrence in Younger Women
ODAC Recommends Approval of Targretin for Advanced CTCL
IOM Assessing Early Breast Cancer Detection Technologies
CRFA Honors Three With Its 1999 FrontLine Awards
Aromasin, New Hormonal Agent, Approved for Breast Cancer
LEDs Developed by NASA Used to Ablate Brain Tumors
Early Androgen Deprivation Beneficial
Higher-Dose RT May Improve Prostate Cancer Outcome
Learning How to Break Bad News to Patients
Multiple View Ultrasound Aids Breast Lesion Characterization and Biopsy Needle Tracking
Conference Informs Patients About Pancreatic Cancer Treatments
Taxotere Gets FDA OK for Use in NSCLC
NCI Seeks Toxicity Studies of Five Natural Substances
Related Videos
Cretostimogene grenadenorepvec’s efficacy compares favorably with the current nonsurgical standards of care in high-risk, Bacillus Calmette Guerin–unresponsive non-muscle invasive bladder cancer.
Artificial intelligence models may be “seamlessly incorporated” into clinical workflow in the management of prostate cancer, says Eric Li, MD.
Panelists smiling at camera on a blue background.
Panelists smiling at camera on a blue background.
Robust genetic testing guidelines in the prostate cancer space must be supported by strong clinical research before they can be properly implemented, says William J. Catalona, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
A panel of 4 experts on multiple myeloma seated at a long table
A panel of 4 experts on multiple myeloma seated at a long table
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Related Content
Patients receiving neoadjuvant chemotherapy plus radical nephroureterectomy for upper tract urothelial carcinoma appear more likely to experience nodal downstaging.

Chemo/Nephroureterectomy Increases pCR Likelihood in Urothelial Carcinoma

December 2nd 2023
Article

Patients receiving neoadjuvant chemotherapy plus radical nephroureterectomy for upper tract urothelial carcinoma appear more likely to experience nodal downstaging.

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Tanios S. Bekaii-Saab, MD, Speaks to Expanding Horizons in CRC Treatment

November 27th 2023
Podcast

Personalized therapy tailored for mutation status is something to expect in the coming years for colorectal cancer treatment, notes Tanios S. Bekaii-Saab, MD.

Findings from a retrospective analysis indicate that treatment in non-academic cancer centers correlates with a decreased rate of immunotherapy use among patients with advanced clear cell renal cell carcinoma.

Data Show Barriers to Immunotherapy Access in Clear Cell RCC Population

December 1st 2023
Article

Findings from a retrospective analysis indicate that treatment in non-academic cancer centers correlates with a decreased rate of immunotherapy use among patients with advanced clear cell renal cell carcinoma.

New treatment updates could help find more patient subtypes to target and treat in the world of CRC.

Multidisciplinary Care and New Treatment Options in CRC

November 20th 2023
Podcast

New treatment updates could help find more patient subtypes to target and treat in the world of CRC, according to Kristen K. Ciombor, MD, MSCI.

More than half of the patients with non–muscle-invasive bladder cancer in the BOND-003 trial achieve a complete response at 6 months following treatment with cretostimogene grenadenorepvec.

Cretostimogene Grenadenorepvec Yields Durable Responses in NMIBC

December 1st 2023
Article

More than half of the patients with non–muscle-invasive bladder cancer in the BOND-003 trial achieve a complete response at 6 months following treatment with cretostimogene grenadenorepvec.

Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received.

CAR T-cell Therapy Remains Preferred Options for Relapsed/Refractory Multiple Myeloma

December 1st 2023
Article

Experts in the field of multiple myeloma gathered to discuss considerations prior to treatment including frailty and the number of lines of previous therapy a patient has received.